US equities
|
SPCX
$168.15
▲+5.78%
NVDA
$237.21
▲+1.39%
MU
$1,064.62
▼-0.95%
TSLA
$378.22
▲+2.06%
MSFT
$526.11
▲+1.66%
INTC
$116.91
▼-2.03%
SNDK
$1,720.68
▲+0.04%
META
$745.30
▲+2.37%
SPCX
$168.15
▲+5.78%
NVDA
$237.21
▲+1.39%
MU
$1,064.62
▼-0.95%
TSLA
$378.22
▲+2.06%
MSFT
$526.11
▲+1.66%
INTC
$116.91
▼-2.03%
SNDK
$1,720.68
▲+0.04%
META
$745.30
▲+2.37%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Dianthus Therapeutics, Inc. - Common Stock
(NQ:
DNTH
)
86.25
-1.96 (-2.22%)
Delayed Quote
Updated: 11:06 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dianthus Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
↗
May 10, 2024
Via
Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
↗
May 09, 2024
DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 09, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
↗
April 18, 2024
Via
Benzinga
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
↗
February 15, 2024
Via
Benzinga
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
↗
January 22, 2024
Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement.
Via
Benzinga
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 11, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
March 22, 2024
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
Via
Benzinga
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
↗
March 22, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Via
Benzinga
Topics
Stocks
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
↗
March 21, 2024
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
February 26, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023
↗
December 14, 2023
Dianthus Therapeutics just reported results for the third quarter of 2023.
Via
InvestorPlace
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
↗
November 22, 2023
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
↗
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
↗
September 28, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
